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Abstract
Purpose Bilobar colorectal liver metastases (CRLM) are
often considered incurable or associated with poor progno-
sis even after R0 resection. In this single-center study, we
evaluate the impact of CRLM spreading on recurrence-free
survival (RFS) and cancer-specific overall survival (CSS)
after R0 resection of CRLM with respect to multimodal
treatment strategies including perioperative chemotherapy
and multistep resections.
Methods Between January 2001 and December 2010, R0
resection could be achieved in 70 patients with bilobar and
100 with unilobar CRLM. Extent of disease, perioperative
chemotherapy, surgical procedures, adjuvant treatment, his-
topathological workup, RFS, and CSS were compared be-
tween both cohorts.
Results Forty-six (66 %) patients with bilobar and 26
(26 %) patients with unilobar CRLM received preoperative
chemotherapy (p<0.001). For bilobar CRLM, more extend-
ed and multistep resection including portal vein occlusion
were performed (29 % versus 3 %; p<0.001). Morbidity
(39 % versus 28 %, p00.183) and mortality (1 % versus
3 %, p00.644) rates were comparable in both patients’
cohorts. Postoperative therapy was applied in adjuvant in-
tent to 42 (60 %) versus 51 (51 %) patients (p00.275). The
5-year RFS and CSS rates were 24 % versus 31 % (p0
0.169) and 42 % versus 55 % (p00.131), respectively.
Conclusions To our single-center experience, there is no sig-
nificant effect of CRLM spreading (bilobar versus unilobar)
on RFS and CSS rates. Bilobar CRLM are more likely to
require extended multimodal efforts to achieve R0 resection.
Keywords Bilobar colorectal liver metastases . Liver
resection .Multimodal treatment . Two-stage resection
Introduction
Surgical resection of colorectal liver metastases (CRLM) is
the only treatment offering the prospect of long-term sur-
vival with reported 5-year survival rates of up to 58 % in
highly specialized centers [1, 2]. Unfortunately, only 20–
30 % of all patients with CRLM are resectable at the time of
diagnosis even when assessed by an experienced hepatobili-
ary surgeon [3]. To increase the resectability rate,
Electronic supplementary material The online version of this article
(doi:10.1007/s00384-012-1455-1) contains supplementary material,
which is available to authorized users.
K. Homayounfar (*) : L. C. Conradi : T. Sprenger : T. Lorf :
M. Niessner :H. Becker : T. Liersch : B. M. Ghadimi
Department of General and Visceral Surgery,





Department of Hematology and Oncology,
University Medical Center, Georg August University Göttingen,
Göttingen, Germany
A. Bleckmann : T. Beissbarth
Department of Medical Statistics, University Medical Center,
Georg August University Göttingen,
Göttingen, Germany
C. O. Sahlmann : J. Meller
Department of Nuclear Medicine, University Medical Center,
Georg August University Göttingen,
Göttingen, Germany
Int J Colorectal Dis (2012) 27:1359–1367
DOI 10.1007/s00384-012-1455-1
preoperative chemotherapy [4] and two-stage liver resec-
tions [5, 6] with portal vein occlusion (PVO) have been
evaluated in the last decade within clinical trials and have
proven benefit with an additional 25–75 % of selected
patients achieving secondary resectability of their CRLM.
Bilobar distribution of CRLM is a major reason for primary
unresectability and has been identified as negative prognostic
parameter in previous studies [7, 8]. Patients with bilobar
CRLM are significantly less often referred to a hepatobiliary
surgeon although resection rates in referred patients did not
differ between unilobar and bilobar disease [9]. However, with
the implementation of interdisciplinary multimodal treatment
strategies, the patient cohort suitable for liver resection now-
adays consists not only of primarily resectable but also con-
verted primarily irresectable patients. Accordingly, the extent
of disease in patients deemed resectable quantified by Fong’s
clinical risk score [10] increased during the last decade [11].
Furthermore, response to preoperative chemotherapy itself,
which is mandatory in initially unresectable patients, is a
positive predictor of survival [12]. In consequence, the current
biological impact of bilobar hepatic spreading in patients with
CRLM is unclear.
Therefore, the aim of the present single-center study was to
evaluate the extent of oncological treatment applied for R0
resection in patients with bilobar versus unilobar CRLM and
to compare the consecutive recurrence-free (RFS) and overall
cancer-specific survival (CSS) after R0 resection considering
interdisciplinary multimodal treatment options including in-
tensified chemotherapy and extended liver resections.
Patients and methods
Study population
From January 2001 to December 2010, 170 patients under-
went histopathologically confirmed complete (R0) resection
(tumor-free resection margin ≥0.1 cm) of all CRLM at the
Department of General and Visceral Surgery, University
Medical Center Göttingen. One hundred thirteen of these
patients presented with unilobar disease based on preopera-
tive staging, but in 13 cases, additional CRLM in the con-
tralateral liver lobe were detected at the time of liver
resection. These 13 patients together with the 57 patients
initially diagnosed with bilobar hepatic spreading (multiple
bilobar CRLM or large involvement of both lobes by a
central metastasis) represent the cohort of patients with
bilobar CRLM and in this study were compared with the
100 patients with unilobar CRLM. Data on primary tumor
treatment, CRLM-directed treatment strategies, periopera-
tive outcome, and survival were prospectively collected in
a database. The local ethics committee approved the study
and all procedures were in accordance with the Helsinki
Declaration of 1975, as revised in 1983.
Table 1 summarizes the clinicopathological baseline data
concerning treatment of the primary colorectal cancer in all
170 patients. With median 59 (95 % CI 34–75) versus 63
(95 % CI 41–79) years, patients with bilobar CRLM were
significantly younger than those with unilobar disease (p0
0.019). In one patient with locally advanced rectal cancer
and synchronous bilobar CRLM, the neoadjuvant treatment
did not comprise standard radiochemotherapy but intensi-
fied systemic chemotherapy with oxaliplatin alone accord-
ing to the referring oncologist’s discretion. In six patients,
histopathological workup identified tumor involvement at
the resection margin in the primary rectal tumor specimen.
However, staging prior to liver-directed therapy did not
indicate local recurrence in any of these patients. Apart from






Agea 63 [41–79] 59 [34–75] 0.019
Gender 0.266
Female 44 (44 %) 24 (34 %)
Male 56 (56 %) 46 (66 %)
Primary tumor 0.755
Colon 56 (56 %) 41 (59 %)
Rectumb 44 (44 %) 29 (41 %)
Neoadjuvant therapy 0.116
Yes 18 (18 %) 6 (9 %)
No 82 (82 %) 64 (91 %)
T stage 0.535
<3 19 (19 %) 10 (14 %)
≥3 81 (81 %) 60 (86 %)
Nodal status 0.276
<1 52 (52 %) 30 (43 %)
≥1 48 (48 %) 40 (57 %)
Grading 0.245
<3 90 (90 %) 58 (83 %)
≥3 10 (10 %) 12 (17 %)
Resection status 0.083
0 99 (99 %) 65 (93 %)
≥1 1 (1 %) 5 (7 %)
UICC stage 0.082
≤2 33 (33 %) 17 (24 %)
3 26 (26 %) 12 (17 %)
4 41 (41 %) 41 (59 %)
Adjuvant chemotherapy 0.136
Yes 37 (37 %) 18 (26 %)
No 63 (63 %) 52 (74 %)
a Expressed as median [95 % CI]
b Up to 16 cm from the anal verve measured by rigid rectoscopy
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age, there was no significant difference in relevant parame-
ters between the two distinct study cohorts.
Staging procedures and treatment algorithm for CRLM
Standardized pretherapeutical staging included clinical ex-
amination, chest-X-ray, abdominal computed tomography
(CT) or magnetic resonance imaging (MRI), and serum
level of carcinoembrionic antigen (CEA). Starting in Janu-
ary 2006, staging was routinely extended by thoracic CT
and 18F-fluorodeoxyglucose–positron emission tomography
(FDG–PET). Prior to treatment onset in our department,
patients were discussed in an interdisciplinary tumor board
of medical as well as surgical oncologists, hepatobiliary
surgeons, radiooncologists, and radiologists to define the
individual multimodal treatment concept with special con-
sideration of preoperative systemic chemotherapy and/or the
need for two-stage hepatectomy. The latter was intended
when the future remnant liver volume to body weight ratio
was calculated to be less than 0.5 % [13].
Patients scheduled for preoperative systemic chemotherapy
were re-evaluated every 3 months for secondary resectability.
Tumor response to preoperative chemotherapy was measured
by an experienced radiologist using the RECIST (Response
Evaluation Criteria In Solid Tumors) criteria and classified as
complete response, partial response, stable disease, or progres-
sive disease [14]. Liver resection was performed according to
established surgical standard operating procedures. Intraoper-
ative ultrasound was used routinely prior to resection proce-
dures to detect previously occult CRLM. In patients scheduled
for two-stage hepatectomy, the first-stage procedure consisted
of surgical exploration of the abdominal cavity, tumor clear-
ance of the future remnant liver segments, and PVO on the
side of predominant metastatic load. During the phase of
PVO-induced liver hypertrophy, no additional chemotherapy
was administered to avoid cumulative morbidity. The second-
stage procedure with extended hemihepatectomy/trisectorec-
tomy was planned 6–8 weeks after PVO. Postoperative liver
insufficiency was defined by prothrombin time <50 % and
serum bilirubin >50 μmol/l on post-op day 5 [15]. To estimate
the risk of tumor recurrence, both the Fong score [10] and the
Nordlinger score [16] were used. Furthermore, CRLM were
classified according to the mTNM staging system as proposed
by Gayowski et al. [8].
Until July 2008, the Association of Scientific Medical So-
cieties in Germany (AWMF) interdisciplinary guidelines for
the treatment of CRLM recommended a “wait and see” strat-
egy after R0 resection of CRLM [17]. Despite this fact, we
performed two phase II trials investigating the feasibility and
safety of single or repeated anti-CEA radioimmunotherapy
with 131I-labetuzumab (humanized anti-CEA immunoglobulin
G1-subclass monoclonal antibody; Immunomedics Inc., Mor-
ris Planes, NJ, USA) after R0 resection of CRLM [18, 19].
Eligible patients with immunohistochemically proven high
CEA expression on CRLM cells were enrolled while the study
was open for recruitment. Other patients requesting postoper-
ative therapy were treated by systemic chemotherapy accord-
ing to the individual tumor board discretion and based on
current treatment regimens as established for adjuvant treat-
ment of primary colorectal cancer.
Statistical analysis
Statistical analysis was performed using the Statistical Com-
puting Software R [20]. Survival analysis was calculated
from the date of liver resection on time to event data (i.e.,
time to cancer progression or time to cancer-specific death)
using the R package survival. Survival data was visualized
using Kaplan–Meier plots and significance was calculated
using the Cox proportional hazards model. Significance for
comparison between cohorts was calculated using Fisher’s
exact test for categorical variables or variables that were
discretized (e.g., gender, tumor stage, type of therapy) and
using the Wilcoxon test for numeric variables (e.g., age, size
of metastasis). p values <0.05 were considered significant.
Results
Preoperative treatment
Detailed data on CRLM treatment are displayed in Table 2. By
preoperative staging, patients with bilobar CRLM had signif-
icantly more metastases than patients with unilobar hepatic
spreading (p<0.001). Furthermore, patients with bilobar
CRLM were more often scheduled for preoperative 5FU-
based systemic chemotherapy (p<0.001) and had more often
intensified cytostatic regimens combined with EGF and
VEGF antibodies (p00.043). Additionally, the median num-
ber of applied chemotherapy cycles was higher in patients
receiving EGFR/VEGF antibodies [eight cycles (95%CI 3.2–
24.4) versus four cycles (95%CI 2–14.6); p<0.001]. Because
of CRLM progression, the initiated first-line regimen needed
to be modified in equivalent proportions of both patients’
cohorts (11 % and 12 %, respectively; p01.0). Preoperative
chemotherapy of CRLM resulted in clinical complete re-
sponse, partial response, stable disease, and progressive dis-
ease in one (1 %), 28 (39 %), 32 (44 %), and 11 (15 %)
patients, respectively. However, even the latter were deemed
technically resectable according to restaging and scheduled
for surgery based on excellent performance status and request.
Surgical procedures
Differentiating between minor resections (<hemihepatec-
tomy) versus major resections (≥hemihepatectomy), no
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significant difference in the extent of liver resections between
the two study cohorts could be detected (p00.061). However,
by analyzing the performed types of resection in detail
(Fig. 1), this supposed equivalence could be traced back to a
higher rate of standard hemihepatectomy in patients with
unilobar CRLM (n036 versus n06; p<0.001) while extended
hemihepatectomies and trisectorectomies were performed sig-
nificantly more often in patients with bilobar CRLM (n037
versus n010; p<0.001). Furthermore, 29 % of patients with
bilobar CRLM but only 3 % of those with unilobar disease (p
<0.001) had to be enrolled into two-stage procedures with
PVO to ensure sufficient postoperative liver function. To note,








No. of liver metastases
preoperatively
<0.001
1 77 (77 %) 15 (21 %)a
>1 23 (23 %) 55 (79 %)
Median number of liver
metastases
pretherapeuticalb




3 [1.1–9.5] 3 [1–10] 0.454
Preoperative chemotherapy <0.001
No 74 (74 %) 24 (34 %)
Yes 26 (26 %) 46 (66 %)
5FU 6 (23 %) 3 (7 %)
5FU+oxaliplatin 14 (54 %) 32 (70 %)
5FU+irinotecan 6 (23 %) 11 (24 %)
Antibody containing regimen 0.043
Yes 5 (19 %) 20 (43 %)
No 21 (81 %) 26 (57 %)
Number of cycles 5 [1.6–12.8] 6 [2–23] 0.675
More than one line 1.000
Yes 3 (12 %) 5 (11 %)
No 23 (88 %) 41 (89 %)
Type of resectionc 0.061
Minor 54 (54 %) 27 (39 %)




Morbidity rate 28 (28 %) 27 (39 %) 0.183
Cardiopulmonary 7 4
Renal 1 0 0.009
Bilioma 4 10 ┐
Liver insufficiencyd 3 5 ┘




Mortality rate 3 (3 %) 1 (1 %) 0.644
Number of liver metastases
pathological
<0.001
1 73 (73 %) 17 (24 %)
>1 27 (27 %) 53 (76 %)
Median number of liver
metastases pathologicalb














<1 cm 53 (53 %) 54 (77 %)
≥1 cm 47 (47 %) 16 (23 %)
mT stage [8] <0.001
1 15 (15 %) 2 (2 %)
2 65 (65 %) 6 (9 %)
3 20 (20 %) 1 (1 %)
4 0 (0 %) 61 (87 %)
Fong score [10] <0.001
0–2 48 (48 %) 60 (86 %)
3–5 52 (52 %) 10 (14 %)
Nordlinger score [16] <0.001
0–2 42 (42 %) 10 (14 %)
3–4 49 (49 %) 50 (71 %)
5–6 9 (9 %) 10 (14 %)
Adjuvant therapy 0.275
No 49 (49 %) 28 (40 %)
Yes 51 (51 %) 42 (60 %)
Systemic chemotherapy 25 11
5FU 2 (8 %) 2 (18 %)
5FU+oxaliplatin 13 (52 %) 6 (55 %)




Yes 3 (12 %) 2 (18 %)
No 22 (88 %) 9 (82 %)
Radioimmunotherapy 26 31
Number of cycles
Systemic chemotherapy 5 [2–12] 3 [1.3–11.8] 0.488
Radioimmunotherapy 2 [1–2] 1 [1–2] 0.205
a Six of these 15 patients had unilobar disease at initial staging
b Expressed as median [95 % CI]
cMinor: <hemihepatectomy; major: ≥hemihepatectomy
dDefined by prothrombin time <50 % and serum bilirubin >50 μmol/
l on post-op day 5 [15]
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in nine patients with bilobar CRLM prior to preoperative
chemotherapy, CRLM could only be detected in one liver
lobe during surgery. These patients consecutively underwent
unilobar resection and had pathological mT1–3 stages accord-
ing to Gayowski’s classification [8].
The overall morbidity rate was comparable in both study
cohorts (28 % versus 39 %; p00.183) but bilioma formation
and liver insufficiency were more frequent in patients with
bilobar CRLM (p00.009). One patient with bilobar and
three patients with unilobar CRLM died postoperatively
because of liver failure after trisectorectomy (n02), acute
hemorrhage (n01), and pneumonia (n01) resulting in a
mortality rate of 2.4 %.
Histopathological workup
Corresponding to the preoperative staging data, the histo-
pathological workup including lamellation (1-cm slices) of
the whole specimen identified more CRLM within the co-
hort of patients with bilobar hepatic spreading (p<0.001).
Furthermore, the proportion of patients with a minimal
resection margin below 1 cm was significantly higher in
the cohort with bilobar CRLM (p00.002). The use of clin-
ical risk scores resulted in a heterogeneous pattern. Accord-
ing to the Nordlinger score [16], 15 % of patients with
bilobar CRLM were classified as low risk while 85 % were
deemed to have an intermediate/high risk of tumor recur-
rence. For patients with unilobar CRLM, nearly equivalent
proportions of patients were grouped into low-risk (42 %)
and intermediate/high-risk (58 %) categories. In contrast,
the application of the Fong score [10] resulted in classifica-
tion of 86 % of patients with bilobar CRLM into the low-
risk group while for patients with unilobar CRLM, risk
stratification results (48 % low and 52 % high risk) were
comparable to those of the Nordlinger score.
Postoperative treatment
The proportions of patients receiving postoperative adjuvant
therapy (either radioimmunotherapy or systemic chemother-
apy) were comparable (p00.275) between the two study
cohorts. Similar to the preoperative setting, oxaliplatin was
the predominant extension to 5FU-based chemotherapy.
Survival
Median follow-up was 30.0 (95 % CI 3.3–76.7) months for
patients with bilobar and 35.7 (95 % CI 1.6–108.2) months
for patients with unilobar CRLM (p00.223). During follow-
up, one patient died because of prostate cancer and eight
patients died non-cancer related without evidence of recur-
rent disease. None of the patients developed metastatic
recurrence more than 36 months after R0 resection of
CRLM. Table 3 displays the localization of second meta-
static recurrence for bi- versus unilobar CRLM. There was
no significant difference in either recurrence rate (p00.327)
Fig. 1 Type of resection in
unilobar (n0100) versus bilobar
(n070) CRLM. The predominant
surgical procedures were wedge
resections and standard
hemihepatectomies in patients




with bilobar CRLM. In nine
patients with bilobar CRLM prior
to preoperative chemotherapy,
CRLM could only be detected in
one liver lobe during surgery.
These patients consecutively
underwent unilobar resection
Table 3 Data on second meta-
static recurrence after R0 resec-









All 62 (100 %) 49 (100 %) 0.3273
Intrahepatic only 24 (39 %) 27 (55 %) 0.1842
Intra- and extrahepatic 6 (10 %) 5 (10 %)
Extrahepatic only 32 (52 %) 17 (35 %)
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or pattern of recurrence (p00.184). Median RFS was 10.6
(95 % CI 6.64–17.1) months for patients with bilobar and
16.1 (95 % CI 10.3–28.6) months for patients with unilobar
CRLM. Consecutive median CSS was 45.9 (95 % CI
38.4–∞) months and 75.5 (95 % CI 50.9–∞) months, re-
spectively. RFS rates (Fig. 2) in patients with bilobar CRLM
(24 % at 3 years, 24 % at 5 years) were not significantly
different from patients with unilobar CRLM (32 % at
3 years, 31 % at 5 years, p00.169). The consecutive CSS
rates (Fig. 3) in patients with bilobar disease (67 % at
3 years, 42 % at 5 years) were also not significantly different
to those in patients with unilobar CRLM (70 % at 3 years,
55 % at 5 years, p00.131). Because some patients had died
for non-colorectal cancer reasons, we also calculated overall
survival (OS) rates but could not observe a significant
difference between bi- and unilobar CRLM either (p0
0.098). Univariate analysis for the study population (n0
170) revealed a trend in RFS (p00.06) and a significant
difference in CSS (p00.007) for those patients with a FONG
score ≤2 versus >2. In multivariate analysis with stratifica-
tion for bilobar and unilobar CRLM neither for RFS nor for
CSS, a significant difference could be detected (FON-
G*lobes~RFS HR00.7, p00.35; FONG*lobes~CSS HR0
0.9, p00.79). Furthermore, we performed a univariate anal-
ysis according to the stratification for synchronous versus
metachronous CRLM. The analysis for the study population
(n0170) did not show significant differences for RFS (p0
0.179) and CSS (p00.972). The multivariate analysis with
stratification for bilobar and unilobar CRLM revealed nei-
ther for RFS (synchronous/metachronous*lobes~RFS HR0
1.8; p00.13) nor for CSS (synchronous/metachronous*-
lobes~CSS HR01.2; p00.74) a difference.
Additionally, we performed a RFS and CSS analysis
excluding the nine patients with solitary central CRLM
involving both liver lobes. Again, there was no significant
difference in RFS (p00.118) or CSS (p00.277) between
both cohorts of bi- and unilobar CRLM.
Discussion
Our single-center data in a consecutive series of R0-resected
patients has not shown a relevant effect of type of CRLM
spreading (bilobar versus unilobar) on RFS (24 % versus
31 %, p00.169) and CSS (42 % versus 55 %, p00.131).
These results are encouraging especially for patients with
bilobar CRLM formerly often deemed to have poor
prognosis.
Preoperative chemotherapy
We applied preoperative chemotherapy mainly for downsiz-
ing of initially unresectable CRLM but also to observe their
chemoresponsiveness. However, chemotherapy was discon-
tinued during liver hypertrophy following PVO as we spec-
ulated about increasing surgical morbidity and impaired
liver volume gain. Although Chun et al. [21] demonstrated
that the combination of preoperative chemotherapy and two-
stage hepatectomy does not increase morbidity rates, the
negative influence on liver hypertrophy is supported by
Fig. 2 Kaplan–Meier curve for
recurrence-free survival in
patients following R0 resection
of CRLM stratified by unilobar
(n0100) versus bilobar (n070)
hepatic spreading
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delayed time to surgery in these patients [22, 23], and
especially those patients with chemotherapy-induced steato-
sis experience significantly less hypertrophy of future rem-
nant liver [23].
Patients with bilobar CRLM received significantly more
often preoperative chemotherapy compared to patients with
unilobar CRLM. This has also been shown by Kornprat et
al. [24]. The median number of preoperative chemotherapy
cycles for patients with bilobar CRLM in our study is in
concordance with other authors [25, 26]. The use of EGFR
and VEGF antibodies was limited to the late study period
(2005–2010) when data on safety and efficacy emerged and
German guidelines recommended more aggressive chemo-
therapy schedules to maximize the downsizing effect in
initially unresectable CRLM [27]. Accordingly, chemother-
apy combined with EGFR/VEGF antibodies was signifi-
cantly more often applied to patients with bilobar CRLM.
Surgical procedures
The predominant surgical procedures were wedge resections
and standard hemihepatectomies in patients with unilobar
CRLM. In contrast, multiple wedge resections, extended
hemihepatectomies, and trisectorectomies were most often
performed in patients with bilobar CRLM. Given that the
majority of patients will experience recurrent metastatic
disease which might be resectable in approximately 30 %
of patients [28], we favored parenchymal-sparing wedge
resections whenever possible. Gold et al. [29] have recently
reported that this approach is associated with decreased
mortality without negatively affecting survival.
Wicherts et al. [6] reported significantly poorer DFS and
OS rates for patients treated within two-stage concepts in-
cluding PVO compared to those with straightforward resec-
tion and without PVO. However, they included patients with
positive resection margins into their analysis. In our own
experience, RFS and CSS rates were comparable between
straightforward resection and two-stage resection with PVO
[30]. This was also shown by Mueller et al. [31]. Covey et
al. [22] discussed a wide indication for two-stage resection
including PVO to compensate the negative effects of preop-
erative chemotherapy. We would restrain such concept as
PVO itself induces measurable intra- and extrahepatic tumor
progression [32].
From the surgical aspect, multiple non-anatomic liver
resections might be associated with a higher surgical risk
than standard hemihepatectomies. As shown by our data
(Fig. 1, Table 2), more complex procedures with a higher
risk for intra-/postoperative complications were necessary in
patients with bilobar CRLM.
Survival
Recently, we have reported that patients with R0 resection of
bilobar CRLM experience a significant survival benefit com-
pared to R1/R2 resections followed by palliative chemother-
apy [30]. These data have been confirmed by Brouquet et al.
[25]. They further demonstrated that surgical exploration with
R1/R2 resection followed by palliative chemotherapy is not
inferior to palliative chemotherapy alone.
Now we focused on the impact of bilobar versus unilobar
spreading of CRLM on RFS and CSS with respect to
Fig. 3 Kaplan–Meier curve of
cancer-specific survival in
patients following R0 resection
of CRLM stratified by unilobar
(n0100) versus bilobar (n070)
hepatic spreading
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multimodal treatment options. We could demonstrate that
neither RFS nor CSS nor OS were significantly different
between patients with bilobar and unilobar CRLM. Within
our cohort of bilobar CRLM, nine patients had solitary
metastases with the majority being larger than 6 cm and
substantial involvement of both liver lobes. However, as
these might cause bias at least concerning RFS, we addi-
tionally performed RFS and CSS analyses excluding these
nine patients. There was again no significant difference
detectable in RFS and CSS between bilobar and unilobar
CRLM. Kornprat et al. [24] had previously published their
series of 98 patients with four or more CRLM. Fifty-five
percent of these patients were treated by preoperative and
92 % by postoperative (adjuvant) chemotherapy. In univar-
iate analysis, the type of CRLM spreading was not associ-
ated with survival. However, they included patients with
positive resection margins and extrahepatic disease into
their analysis. In contrast, Nikfarjam et al. [33] reported
bilobar spreading of CRLM to be an independent negative
prognostic parameter for long-term survival in the era of
effective chemotherapy. Consistently to Kornprat et al. [24],
they did not design a comparative study but performed uni-
and multivariate analyses to identify prognostic parameters
in their patient cohort of 64 patients. Furthermore, complete
resection of all CRLM was performed only in 41 patients
while in the remaining 23 patients radiofrequency ablation
was used in addition to liver resection. Moreover, they also
included patients with known extrahepatic disease (n05)
and positive resection margins (n05) although Rees et al.
[34] have demonstrated that positive resection margins are
one of the strongest independent negative prognostic param-
eters. To the best of our knowledge, our data are the first
focusing on the aspect of CRLM spreading in R0-resected
patients in respect of multimodal treatment options.
Cummings et al. [35] have demonstrated that the benefit
of liver resection reported by single-center experiences
could be reproduced using a large population-based data-
base. However, only 6.1 % of the identified 13,599 patients
with CRLM underwent liver resection. Most likely a major
reason of low resection rate is unawareness concerning the
possibilities of modern multimodal treatment including ad-
vanced liver resection in patients with bilobar CRLM.
However, a non-critical use of both systemic chemother-
apy and two-stage resections with PVL in patients with
CRLM should be avoided. Although systemic chemother-
apeutical options have evolved in the last decade in partic-
ular in terms of novel monoclonal EGFR and VEGF
antibodies, a significant and substantial benefit of (intensi-
fied) systemic 5FU-based chemotherapy either pre- or post-
operatively on survival has not been demonstrated for
patients with resectable CRLM so far [36–38]. In contrast,
advanced two-stage resections with PVL and intensified
systemic 5FU-based preoperative chemotherapy in patients
with primarily irresectable CRLM have shown to increase
the secondary resection rate and thereby positively influence
survival [4, 39].
Conclusion
We demonstrated that the efforts and special risks of multi-
modal treatment in patients with bilobar CRLM are justified
by encouraging survival rates when R0 resection becomes
possible. Furthermore, there was no marked effect of CRLM
spreading (bilobar versus unilobar) on RFS and CSS rates.
Therefore, all patients with CRLM regardless of type of
hepatic spreading need to be discussed within interdisciplin-
ary tumor boards under participation of experienced hepa-
tobiliary surgeons. All efforts should be undertaken to
achieve R0 resection of all CRLM.
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